當(dāng)前位置：   首頁 > 需求大廳

 >  特色服務(wù) 

求購歐洲藥典EP9.0中關(guān)于腺相關(guān)病毒的章節(jié)內(nèi)容   [更多]

高價求購《預(yù)充式導(dǎo)管沖洗器》相關(guān)信息，內(nèi)容要清晰，價格好商量。。。。   [更多]

標(biāo)題： 1、Perindopril-based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial 2、Management of hypertension with the fixed combination of perindopril and amlodipine in daily clinical practice: results from the STRONG prospective, observational, multicenter study 3、Bioequivalence study of two perindopril erbumine tablet formulations in healthy volunteers 4、Development and in vitro/in vivo evaluation of immediate release perindopril tablets 5、The advantages of combination therapy on hypertension: development of immediate release perindoprilindapamide tablet and assessment of bioequivalence studies 6、Does Chinese ethnicity affect the pharmacokinetics and pharmacodynamics of angiotensin-converting enzyme inhibitors? - PubMed - NCBI 7、Drug Dev Ind Pharm. 2013 Jul;39(7):996-1004. doi: 10.3109/03639045.2012.689765. Epub 2012 May 25. A potent preparation method combining neutralization with microfluidization for rebamipide nanosuspensions and its in vivo evaluation. Shi Y1, Zou M, An Y, Ji Z, Gao P, Cheng G. 8、Drug Dev Ind Pharm. 2006 Jul;32(6):651-60. Production of an extremly low dose procaterol HCl preparation by fluidized-bed coating method: in vitro and in vivo evaluation. Yu TW1, Chen RR, Gau CS. 9、Enhancement of solubility and dissolution of cilostazol by solid dispersion technique. Park JH, Choi HK. Arch Pharm Res. 2015 Jul;38(7):1336-44. doi: 10.1007/s12272-014-0547-6. Epub 2015 Jan 8. 10、Solid-state amorphization of rebamipide and investigation on solubility and stability of the amorphous form. Xiong X, Xu K, Li S, Tang P, Xiao Y, Li H. Drug Dev Ind Pharm. 2017 Feb;43(2):283-292. doi: 10.1080/03639045.2016.1239627. Epub 2016 Oct 6. 要求：將符合要求的文獻(xiàn)PDF格式打包上傳   [更多]

求購“USP Monographs: Mycophenolate Mofetil for Injection”《 USP41-NF36 》的藥典標(biāo)準(zhǔn)一份.   [更多]

標(biāo)題：重金求購Gluconolactone《 USP41-NF36 》的藥典標(biāo)準(zhǔn)一份. 詳細(xì)要求： 需求名稱：Gluconolactone《 USP41-NF36 》的藥典標(biāo)準(zhǔn) 具體要求：《 USP41-NF36 》 要求時間：請在2017年12月29日之前 交稿方式：直接點(diǎn)擊交稿在線交稿就是了，我會每天過來看的，謝謝各位藥智的戰(zhàn)友們   [更多]

求助國內(nèi)外抗輻射研究最新進(jìn)展及相關(guān)文獻(xiàn)，若有資源的朋友，請以投稿的方式進(jìn)行投稿，謝謝。   [更多]

求購“Butylated hydroxytoluene. Butylhydroxytoluene.”歐洲藥典標(biāo)準(zhǔn)一份.   [更多]

求購“USP Monographs: Gentamicin Sulfate Ophthalmic Ointment”美國藥典標(biāo)準(zhǔn)一份，要求最新版的   [更多]

求購次氯酸鈉，紅外、紫外、氣相、液相、核譜、粉能射譜、單晶結(jié)構(gòu)圖，以及相關(guān)的相關(guān)文獻(xiàn)，至少四個文獻(xiàn) 化合物CA登記號(CAS): 7681-52-9   [更多]

標(biāo)題： 1、Morisset M et al. Allergy to cow milk proteins contaminating lactose, common excipient of dry powder inhalers for asthma. J Allergy Clin Immunol 2006; 117(Suppl. 1): 95 2、Safety and tolerability of selumetinib as a monotherapy, or in combination with docetaxel as second-line therapy, in Japanese patients with advanced solid malignancies or non-small cell lung cancer. 3、Preparation and characterization of a cocrystalline suspension of [LysB28,ProB29]-human insulin analogue. DeFelippis MR1, Bakaysa DL, Bell MA, Heady MA, Li S, Pye S, Youngman KM, Radziuk J, Frank BH 1、Heterocycles, 2001 , vol. 55, # 2 p. 331 - 352 4、R. G. Strickley, L. Liu, and P. Lapresca. Preclinical parenteral and oral formulations of water insoluble molecules. ISSX Meet- ing, Nashville, TN (USA) Abstract # 291 (1999). (Z) 5、465: A possible genetic signature of DNA repair genes in triple negative breast cancers by a NGS approach 4、Systemic exposure to?atorvastatin?between Asian and Caucasian subjects: a combined analysis of 22 studies. 6、 Evaluation of cardiovascular morbidity associated with adherence to?atorvastatin?therapy. 7、Beta-lactam antibiotics: their role in the management of infections in children 8、China type 2 diabetes treatment status survey of treatment pattern of oral drugs users. J Diabetes. 2015 Mar;7(2):166-73 9、Non‐steroidal anti‐inflammatory drugs and upper gastrointestinal bleeding, a post‐marketing surveillance case‐control study 10、Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. 備注：將符合要求文獻(xiàn)的PDF格式打包上傳   [更多]